Sandbox m ex

Revision as of 20:22, 3 August 2015 by Monalisa Dmello (talk | contribs)
Jump to navigation Jump to search

plam

Malaria Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Malaria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Xray

Ultrasound

CT scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Sandbox m ex On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox m ex

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox m ex

CDC on Sandbox m ex

Sandbox m ex in the news

Blogs on Sandbox m ex

Directions to Hospitals Treating Malaria

Risk calculators and risk factors for Sandbox m ex

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Plasmodium.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Yazan Daaboul, Serge Korjian, Alison Leibowitz [2]

Overview

Malaria is a vector-borne infectious disease caused by protozoan parasites. P. vivax is the most common cause of infection, responsible for about 80% of all malaria cases. P. falciparum, the most significant cause of disease, is responsible for about 15% of infections and 90% of deaths.[1][2]

Causes

P. vivax is the most common cause of infection, responsible for about 80% of all malaria cases. P. falciparum, the most significant cause of disease, is responsible for about 15% of infections and 90% of deaths.[3] The remainder of human malaria infections are caused by P. ovale, P. malariae, and P. knowlesi.


The following table distinguishes between the different strains of Plasmodium species, all of which are causative agents of malarial infection.

Comparison of Plasmodium Species Implicated in Human Malaria ("Malaria". Center for Disease Control and Prevention. Center for Disease Control and Prevention (CDC). Nov. 29 2013. Retrieved Jul 24 2014. Check date values in: |accessdate=, |date= (help))
Strain Clinical Significance
P. falciparum Tertian/subtertian fever (every 48 hours), causes severe malaria in up to 24% of cases, and is frequently drug resistant.
P. vivax

Tertian fever (every 48 hours), results in severe malaria in up to 22% of cases, and is frequently drug resistant. Relapse is common due to the dormant liver phase.

P. ovale Tertian fever (every 48 hours), rarely causes severe malaria or drug resistance. Relapse is common due to dormant liver phase.
P. malariae Quartan fever (every 72 hrs), rarely results in severe malaria or drug resistance. Although dormant liver phase is uncommon, infection persistence is frequently demonstrated.
P. knowlesi Daily fevers, may result in severe malaria in up to 10% of cases, although resistance is rare.
Adapted from Center for Disease Control and Prevention (CDC) - Malaria

References

  1. Mendis K, Sina B, Marchesini P, Carter R (2001). "The neglected burden of Plasmodium vivax malaria" (PDF). Am J Trop Med Hyg. 64 (1-2 Suppl): 97–106. PMID 11425182.
  2. Mendis K, Sina B, Marchesini P, Carter R (2001). "The neglected burden of Plasmodium vivax malaria" (PDF). Am J Trop Med Hyg. 64 (1-2 Suppl): 97–106. PMID 11425182.
  3. Mendis K, Sina B, Marchesini P, Carter R (2001). "The neglected burden of Plasmodium vivax malaria" (PDF). Am J Trop Med Hyg. 64 (1-2 Suppl): 97–106. PMID 11425182.

Template:WikiDoc Sources


q fever microb

Coxiella burnetii
C. burnetii, the causative agent of Q fever
C. burnetii, the causative agent of Q fever
Scientific classification
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gamma Proteobacteria
Order: Legionellales
Family: Coxiellaceae
Genus: Coxiella
Species: C. burnetii
Binomial name
Coxiella burnetii
(Derrick 1939)
Philip 1948

Coxiella burnetii is a species of intracellular, pathogenic bacteria, and is the causative agent of Q fever. The genus Coxiella is morphologically similar to the rickettsia, but with a variety of genetic and physiological differences. C. burnetii are small Gram negative bacteria with two growth phases, as well as a spore form which lies idle in soil.[1] It can survive standard disinfectants, and is resistant to many other environmental changes.[2]

Pathogenesis

The ID50 (the dose needed to infect 50% of experimental subjects) is one via inhalation— i.e. inhalation of one organism will yield disease in 50% of the population. Disease occurs in two states: An acute state presents with headaches, chills, and respiratory symptoms, and an insidious chronic stage.

While most infections clear up spontaneously, treatment with tetracycline or doxycycline appears to reduce the symptomatic duration and reduce the likelihood of chronic infection. A combination of erythromycin and rifampin is highly effective in curing and prevention of disease and so is vaccination with Q-vax vaccine (CSL).


References

  1. Ryan KJ; Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. ISBN 0-8385-8529-9.
  2. Sankaran, Neeraja (2000). "Coxiella burnetii". Microbes and people : an A-Z of microorganisms in our lives. Phoenix, Arizona: The Oryx Press. p. 72. ISBN 1-57356-217-3. "In contrast to other rickettsiae, which are highly sensitive and easily killed by chemical disinfectants and changes in their surroundings, C. burnetii is highly resistant" & "Q fever". Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Viral and Rickettsial Diseases; Viral and Rickettsial Zoonoses Branch. 2003-02013. Retrieved 2006-05-24. Check date values in: |date= (help) "The organisms are resistant to heat, drying, and many common disinfectants."


Anti-malarial Agents

Recommended Indications and Doses of Common Anti-malarial Agents
Anti-malarial Agent Indication Dosing
Chloroquine phosphate P. falciparum from chloroquine-sensitive areas
P. vivax from chloroquine-sensitive areas
All P. ovale
All P. malariae
1g oral load, followed by 500 mg orally at 6, 24, and 48 h
Hydroxychloroquine Same as chloroquine (second line agent) 800 mg oral load, followed by 400 mg orally at 6, 24, and 48 h
Atovaquone-Proguanil P. falciparum from chloroquine-resistant areas 250 mg atovaquone/100 mg proguanil (1 tab) orally 4 times daily for 3 days
Primaquine phosphate Cure of P. vivax and P. ovale (to eliminate hypnozoites) 30 mg orally once daily for 14 days
Clindamycin* P. falciparum or P. vivax from chloroquine-resistant areas 20 mg/kg/day orally for 3 days
or
10 mg/kg IV load, followed by 5 mg/kg IV every 8 hours
Doxycycline* P. falciparum or P. vivax from chloroquine-resistant areas 100 mg orally twice daily for 7 days
or
100 mg IV every 12 hours for 7 days (can switch from

IV to PO)

Tertacycline* P. falciparum or P. vivax from chloroquine-resistant areas 250 mg orally 4 times daily for 7 days
or
250 mg IV 4 times daily for 7 days (can switch from

IV to PO)

Mefloquine P. falciparum or P. vivax from chloroquine-resistant areas except Thailand-Burmese and Thailand-Cambodian border regions 750 mg oral load, followed by 500 mg orally 6-12 hours after initial dose
Quinine sulfate P. falciparum or P. vivax from chloroquine-resistant areas 650 mg orally 3 times daily for 3 days or 7 days if acquired from Southeast Asia
Quinidine gluconate Severe malaria (all species
Unable to tolerate oral agents
Parasitemia>10%
10 mg/kg IV load over 1-2 hours, then 0.02 mg/kg/min continuous infusion for at least 24 hours
Artemether-lumefantrine All P. falciparum (outside USA) 1.5 mg/kg - 9 mg/kg orally twice daily for 3 days
Dihydroartemisinin–piperaquine All P. falciparum (outside USA) 2·5 mg/kg – 20 mg/kg orally once daily for 3 days
Artesunate All P. falciparum (outside USA)
First line IV agent for severe malaria (outside USA)
In severe malaria: 2.4 mg/kg IV or IM load,
followed by 2.4 mg/kg at 12 h and 24 h;
continue injection once daily if necessary

In uncomplicated malaria: Monotherapy not recommended,
4mg/kg orally once daily for 3 days combined with
a single oral dose of sulfadoxine–pyrimethamine 25/1.25 mg/kg
or mefloquine 8 mg/kg orally daily for 3 days

*Used in combination with quinine or quinidine


mx The treatment approach in patients with suspected or confirmed malaria varies according to several factors namely travel history, species of Plasmodium, severity of presentation, and availability of certain therapeutic agents.

Initial Assessment & Severe Malaria

The first step in the management of patients with malaria is to conduct a clinical assessment of status and disease severity, as well as determination of the degree of parasitemia. Signs of severe malarial disease include any of the following: Prostration, impaired consciousness/coma, respiratory distress, convulsions, shock, pulmonary edema, acute respiratory distress syndrome (ARDS), jaundice, abnormal bleeding, severe anemia, hemolysis, hemoglobinuria, acute kidney injury, metabolic acidosis, disseminated intravascular coagulopathy, parasitemia >5%. Patients with severe disease require rapid resuscitation and medical therapy. The most vital step in the management is immediate initiation of appropriate parenteral treatment. Unlike patients who appear stable clinically, patients with severe malaria do not require speciation prior to initiation of medical therapy.

The therapeutic regimen in patients with severe malaria consists of intravenous quinidine gluconate plus either tetracycline, doxycycline, or clindamycin.[1] Other supportive measures include admission to the intensive care unit, continuous monitoring of cardiac function, glycemia, parasitemia, hemoglobin and electrolytes. Exchange transfusions may also be considered in patients with a degree of parasitemia >10%.

Uncomplicated Malaria

In patients with clinically and bacteriologically uncomplicated malaria, speciation is required to tailor medical therapy. For most non-falciparum species, chloroquine remains the first line therapeutic agent. It is important to add primaquine to the treatment regimen in patients with documented P. vivax and P. ovale infections to eradicate liver hypnozoites (dormant liver spores that are responsible for recurrence). Care should be taken in patients with G6PD deficiency as large doses of primaquine can cause significant hemolysis. Patients infected with P. malaria do not require primaquine as the species is not capable of forming hypnozoites.[2] Patients diagnosed with P. falciparum malaria require hospitalization given the risk of progression to severe malaria. These patients have to be monitored on daily basis with a blood film and a full physical exam. The choice of drug in these patients depends on two main factors: the area of acquisition of the parasite, and the center at which the patient is being treated.[1]

Despite being the mainstay of therapy since its introduction, empiric treatment with chloroquine in patients with P. falciparum is no longer recommended due to a sharp increase in resistance. A detailed travel history is important to determine where the infection was acquired. Most malaria endemic countries have reported chloroquine resistant strains, with the exception of Central America west of Panama Canal, Mexico, Hispaniola, certain parts of China, and the Middle East (see figure below). If acquired in any of the latter sites then treatment with chloroquine is adequate. Acquisition from all other endemic countries requires other therapeutic regimens such as oral quinine with either tetracycline, doxycycline, or clindamycin as a first line therapy in the United States, otherwise atovaquone-proguanil or mefloquine if the primary regimen is unavailable.

Worldwide, the treatment of both complicated and uncomplicated P. falciparum malaria requires a combination therapy that includes artemisinin derivatives. According to the 2010 WHO guidelines on the treatment of malaria, the following regimens are first line for the treatment of uncomplicated P. falciparum: artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus mefloquine, and artesunate plus sulfadoxine-pyrimethamin. It is important to note that artemisin monotherapy in not recommended due to increasing resistance. For patients with severe P. falciparum malaria, artesunate IV or IM is first line followed by IV quinidine. The artemisinin derivatives clear parasites very rapidly have been shown to reduce mortality in severe malaria compared with parenteral quinine. Artemisins are not widely available in the United States and their use is not common practice. Only oral artemether plus lumefantrine is available, while IV atresunate can be obtained through the CDC part of an investigational drug protocol. [3]

  1. 1.0 1.1 Griffith KS, Lewis LS, Mali S, Parise ME (2007). "Treatment of malaria in the United States: a systematic review". JAMA. 297 (20): 2264–77. doi:10.1001/jama.297.20.2264. PMID 17519416.
  2. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM (2014). "Malaria". Lancet. 383 (9918): 723–35. doi:10.1016/S0140-6736(13)60024-0. PMID 23953767.
  3. Template:Cite website